| Description | Hypophyllanthin and phyllanthin have antitumour effects against Ehrlich Ascites Carcinoma in mice. |
| In vitro | The activity of P-gp and MRP2 was determined in the uptake assays by monitoring the intracellular accumulation of their specific substrates (calcein acetoxymethyl ester and 5(6)-carboxy-2',7'-dichlorofluorescein diacetate, respectively) with fluorescence spectroscopy. Hypophyllanthin and phyllanthin inhibited P-gp function with comparable potencies, but neither compound affected MRP2 activity. When the lignans were washed out before addition of substrate, the inhibitory action of both compounds against P-gp function was lost. These results suggested the reversibility of the inhibition. Moreover, prolonged exposure of the Caco-2 cells to both lignans (up to 7 days) had no effect on P-gp function[1] |
| Synonyms | 叶下珠次素, (7S,8S,9R)-9-(3,4-二甲氧基苯基)-6,7,8,9-四氢-4-甲氧基-7,8-双(甲氧基甲基)萘并[1,2-D]-1,3-二恶茂 |
| molecular weight | 430.49 |
| Molecular formula | C24H30O7 |
| CAS | 33676-00-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (232.29 mM), Sonication is recommended. |
| References | 1. Phyllanthin and hypophyllanthin inhibit function of P-gp but not MRP2 in Caco-2 cells.J Pharm Pharmacol. 2013 Feb;65(2):292-9. |